Browsing by Author "Munoz, A."

Now showing 1 - 6 of 6
  • No Thumbnail Available
    Item
    Achievement of treatment targets of cardiovascular risk factors in a pilot secondary prevention program in Chile
    (2008) Acevedo, M.; Kraemer, V.; Chamorro, G.; Krogh, G.; Munoz, A.; Corbalan, R.
  • Thumbnail Image
    Item
    Bilateral reversed palmaris longus muscle: a rare anatomical variation
    (VIA MEDICA, 2012) Salgado, G.; Cantin, M.; Inzunza, O.; Munoz, A.; Saez, J.; Macuer, M.
    We report a case of bilateral reversed palmaris longus muscle (PLM). The muscle was tendinous in its upper portion and muscular in its lower portion in both arms. This rare variation has been mentioned only once in the literature as a surgical finding. According to the literature, a reversed PLM may cause a compartment syndrome in the wrist area, carpal tunnel, and Guyon's syndrome. The described variation is also useful to the hand surgeon as a tendon graft a tendon for transfer, or as an anatomical landmark for operations at this area. (Folia Morphol 2012; 71, 1:52-55)
  • No Thumbnail Available
    Item
    Corrigendum to ‘Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia’ (European Journal of Vascular & Endovascular Surgery (2019) 58(1S) (S1–S109.e33), (S1078588419303806), (10.1016/j.ejvs.2019.05.006))
    (2020) Conte, M.S.; Bradbury, A.W.; Kolh, P.; White, J.V.; Dick, F.; Fitridge, R.; Mills, J.L.; Ricco, J.-B.; Suresh, K.R.; Murad, M.H.; Aboyans, V.; Aksoy, M.; Alexandrescu, V.-A.; Armstrong, D.; Azuma, N.; Belch, J.; Bergoeing Reid, Michel Paul; Bjorck, M.; Chakfé, N.; Cheng, S.; Dawson, J.; Debus, E.S.; Dueck, A.; Duval, S.; Eckstein, H.H.; Ferraresi, R.; Gambhir, R.; Garguilo, M.; Geraghty, P.; Goode, S.; Gray, B.; Guo, W.; Gupta, P.C.; Hinchliffe, R.; Jetty, P.; Komori, K.; Lavery, L.; Liang, W.; Lookstein, R.; Menard, M.; Misra, S.; Miyata, T.; Moneta, G.; Munoa Prado, J.A.; Munoz, A.; Paolini, J.E.; Patel, M.; Pomposelli, F.; Powell, R.; Robless, P.; Rogers, L.; Schanzer, A.; Schneider, P.; Taylor, S.; Vega de Ceniga, M.; Veller, M.; Vermassen, F.; Wang, J.; Wang, S.
  • No Thumbnail Available
    Item
    Corrigendum to “Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischaemia” [Eur J Vasc Endovasc Surg 58 (1S) (2019) 1–109>] (European Journal of Vascular & Endovascular Surgery (2019) 58(1S) (S1–S109.e33), (S1078588419303806), (10.1016/j.ejvs.2019.05.006))
    (2020) Conte, M.S.; Bradbury, A.W.; Kolh, P.; White, J.V.; Dick, F.; Fitridge, R.; Mills, J.L.; Ricco, J.-B.; Suresh, K.R.; Murad, M.H.; Aboyans, V.; Aksoy, M.; Alexandrescu, V.-A.; Armstrong, D.; Azuma, N.; Belch, J.; Bergoeing Reid, Michel Paul; Bjorck, M.; Chakfé, N.; Cheng, S.; Dawson, J.; Debus, E.S.; Dueck, A.; Duval, S.; Eckstein, H.H.; Ferraresi, R.; Gambhir, R.; Gargiulo, M.; Geraghty, P.; Goode, S.; Gray, B.; Guo, W.; Gupta, P.C.; Hinchliffe, R.; Jetty, P.; Komori, K.; Lavery, L.; Liang, W.; Lookstein, R.; Menard, M.; Misra, S.; Miyata, T.; Moneta, G.; Munoa Prado, J.A.; Munoz, A.; Paolini, J.E.; Patel, M.; Pomposelli, F.; Powell, R.; Robless, P.; Rogers, L.; Schanzer, A.; Schneider, P.; Taylor, S.; De Ceniga, M.V.; Veller, M.; Vermassen, F.; Wang, J.; Wang, S.
  • Thumbnail Image
    Item
    Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia
    (2019) Conte, M.S.; Bradbury, A.W.; Kolh, P.; White, J.V.; Dick, F.; Fitridge, R.; Mills, J.L.; Ricco, J.B.; Suresh, K.R.; Bergoeing Reid, Michel Paul; Murad, M.H.; Aboyans, V.; Aksoy, M.; Alexandrescu, V.A.; Armstrong, D.; Azuma, N.; Belch, J.; Bjorck, M.; Chakfe, N.; Cheng, S.; Dawson, J.; Debus, E.S.; Dueck, A.; Duval, S.; Eckstein, H.H.; Ferraresi, R.; Gambhir, R.; Garguilo, M.; Geraghty, P.; Goode, S.; Gray, B.; Guo, W.; Gupta, P.C.; Hinchliffe, R.; Jetty, P.; Komori, K.; Lavery, L.; Liang, W.; Lookstein, R.; Menard, M.; Misra, S.; Miyata, T.; Moneta, G.; Prado, J.A.M.; Munoz, A.; Paolini, J.E.; Patel, M.; Pomposelli, F.; Powell, R.; Robless, P.; Rogers, L.; Schanzer, A.; Schneider, P.; Taylor, S.; De Ceniga, M.V.; Veller, M.; Vermassen, F.; Wang, J.S.; Wang, S.M.
  • Thumbnail Image
    Item
    Waning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination
    (SPRINGER INTERNATIONAL PUBLISHING AG, 2023) Tong, X.; McNamara, R. P.; Avendano, M. J.; Serrano, E. F.; Garcia-Salum, T.; Pardo-Roa, C.; Bertera, H. L.; Chicz, T. M.; Levican, J.; Poblete, E.; Salinas, E.; Munoz, A.; Riquelme, A.; Alter, G.; Medina, R. A.
    Efficiency of SARS-CoV-2 vaccines has long been attributed to the neutralising capacity of the antibodies that are produced upon prime-boost vaccinations. Here authors show that upon vaccination with CoronaVac and BNT162b2 vaccines in prime-boost regimens, antibodies with Fc-effector functions to enhance cellular and innate immunity are also produced, albeit with different kinetics., Since the emergence of SARS-CoV-2, vaccines targeting COVID-19 have been developed with unprecedented speed and efficiency. CoronaVac, utilising an inactivated form of the COVID-19 virus and the mRNA26 based Pfizer/BNT162b2 vaccines are widely distributed. Beyond the ability of vaccines to induce production of neutralizing antibodies, they might lead to the generation of antibodies attenuating the disease by recruiting cytotoxic and opsonophagocytic functions. However, the Fc-effector functions of vaccine induced antibodies are much less studied than virus neutralization. Here, using systems serology, we follow the longitudinal Fc-effector profiles induced by CoronaVac and BNT162b2 up until five months following the two-dose vaccine regimen. Compared to BNT162b2, CoronaVac responses wane more slowly, albeit the levels remain lower than that of BNT162b2 recipients throughout the entire observation period. However, mRNA vaccine boosting of CoronaVac responses, including response to the Omicron variant, induce significantly higher peak of antibody functional responses with increased humoral breadth. In summary, we show that vaccine platform-induced humoral responses are not limited to virus neutralization but rather utilise antibody dependent effector functions. We demonstrate that this functionality wanes with different kinetics and can be rescued and expanded via boosting with subsequent homologous and heterologous vaccination.